Company: DHR
Filing Date: 2025-04-22
Form Type: 10-Q
Source: 0000313616-25-000088
Chunk: 87

Company: DANAHER CORP /DE/
Filing Date: 2025-04-22
Form: 10-Q
Item: Item 8
Chunk 87
---
 price and unit sales and references to productivity improvements generally refer to improved cost-efficiencies resulting from the ongoing application of the Danaher Business System.

Sales Decline and Core Sales Growth

% Change Three-Month Period Ended March 28, 2025 vs. Comparable 2024 PeriodTotal sales decline (GAAP)(1.0)%Impact of:Acquisitions/divestitures(0.5)%Currency exchange rates 1.5 %Core sales growth (non-GAAP)— %

Operating Profit Performance 

Operating profit margins decreased 40 basis points from 22.6% during the three-month period ended March 29, 2024 to 22.2% for the three-month period ended March 28, 2025.  

First quarter 2025 vs. first quarter 2024 operating profit margin comparisons were unfavorably impacted by:

•The impact of product mix, reduced leverage on the Company’s operations and administrative cost structure and the impact of currency exchange rates - 30 basis points

•Incremental dilutive effect in 2025 of acquired businesses and the impact of a product line disposition which did not qualify as discontinued operations - 25 basis points

•First quarter 2025 impairment charge related to a facility in the Biotechnology segment - 25 basis points

23

First quarter 2025 vs. first quarter 2024 operating profit margin comparisons were favorably impacted by:

•First quarter 2024 acquisition-related fair value adjustment to inventory - 40 basis points

Business Segments

Sales by business segment for each of the periods indicated were as follows ($ in millions):

 Three-Month Period Ended March 28, 2025March 29, 2024Biotechnology$1,612 $1,524 Life Sciences1,680 1,745 Diagnostics2,449 2,527 Total$5,741 $5,796 

For information regarding the Company’s sales by geographical region, refer to Note 4 to the accompanying Consolidated Condensed Financial Statements.

BIOTECHNOLOGY

The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a broad range of equipment, consumables and services that are primarily used by customers to advance and accelerate the research, development, manufacture and delivery of biological medicines.  The Company’s solutions support a broad range of biotherapeutics including monoclonal antibodies, recombinant proteins, replacement therapies such as insulin and vaccines, as well as novel cell, gene,